Bruker Announces First 1.2 GHz NMR Installation in the United States at The Ohio State University - Funded by the U.S. National Science Foundation
19 Dezember 2023 - 3:41PM
Business Wire
Novel GHz-class NMR systems are enabling
unprecedented life science and materials research in functional
structural biology, drug discovery, metabolomics and cleantech
research.
Bruker Corporation, the leading provider of nuclear magnetic
resonance (NMR) spectroscopy solutions for life and materials
research, today announced the successful installation of a 1.2
Gigahertz (GHz) NMR system at the National Gateway Ultrahigh Field
NMR Center (https://gateway-nmr.osu.edu/) at The Ohio State
University.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20231219164773/en/
New 1.2 GHz AVANCE® NMR system at The
Ohio State University (Photo: Business Wire)
Ultra-high field NMR is complementary to other structural
biology technologies in that NMR can measure functional molecular
dynamics and structural rearrangements for functional structural
biology. Key areas of NMR applications include organic chemistry,
macromolecular structure determination, drug-target binding,
protein-protein or protein-RNA interactions – all at close to
native conditions and in solution, or even in situ in cell
membranes. NMR also has unique capabilities to elucidate ‘hidden’,
short-lived protein transition states from healthy to disease
biology, e.g., in active enzymes or in the onset of protein
aggregation in neurodegenerative diseases. Finally, many key
proteins in cell biology, e.g., transcription factors, or proteins
implicated in cancer, infectious disease or neurodegeneration are
intrinsically disordered, or partially disordered, and GHz-class
NMR enables pivotal research of functional molecular disorder in
many areas of pathobiology.
The U.S. National Science Foundation (NSF) has played a crucial
role in funding the 1.2 GHz NMR instrument at The Ohio State
University. Dr. Robert Fleischmann, who is the NSF program officer
of the grant that funded the 1.2 GHz NMR instrument (NSF Award 1935913),
considers this instrument an important advancement of the
scientific infrastructure in the United States: "Supported by one
of the first awards made by NSF’s Directorate for Biological
Sciences as part of the agency’s Midscale Research Infrastructure
program, the 1.2 GHz NMR will fulfill a national need and enable
U.S. researchers to be competitive in a global research environment
and advance the U.S. bioeconomy. It’s a prime example of the type
of infrastructure the program was designed to support – the
critical tools and technology that fall between major research
instrumentation and large facilities.”
The 1.2 GHz AVANCE® NMR spectrometer is a state-of-the-art
instrument that enables high-resolution liquid and solid-state NMR
experiments. It will be used by researchers at Ohio State and
across the U.S. to study advanced materials, e.g., for batteries,
and the structure and dynamics of biological molecules, with the
goal of advancing the understanding of the underlying mechanisms of
diseases, such as cancer, cardiovascular disease, viral infections,
or Alzheimer’s disease.
Dr. Rafael Brüschweiler, a professor of chemistry and
biochemistry at The Ohio State University, and PI of the National
Gateway Ultrahigh Field NMR Center, is a leading expert in NMR. His
cross-disciplinary research has been instrumental in the
development of new techniques to understand the role of protein
dynamics and interactions, as well as to analyze complex biological
mixtures in metabolomics.
Professor Brüschweiler stated: “The installation of the 1.2 GHz
NMR instrument gives us the capability to explore the structure and
dynamics of biological molecules at an unprecedented level of
detail. This breakthrough will enable significant advances in our
understanding of how these molecules function, ultimately leading
to the development of new treatments for diseases. We are excited
about the possibilities that lie ahead and look forward to the
discoveries that this new technology will facilitate."
Dr. Falko Busse, President of Bruker BioSpin, described the
installation of the OSU 1.2 GHz NMR as a milestone: “We are honored
to work with The Ohio State University to bring this groundbreaking
technology to the United States. GHz-class NMR represents a leap
forward in the ability to study the structure and function of
biological molecules. We look forward to the scientific impact that
GHz-class NMR will have on cutting-edge life science and materials
research at OSU and in the US.”
The Ohio State University has the first 1.2 GHz NMR in the
United States, a milestone in advancing US life science and
materials research infrastructure, with leadership and funding by
the National Science Foundation. In Europe, eight 1.2 GHz NMRs are
installed, with four more on order, while in Asia-Pacific the Korea
Basic Science Institute (KBSI) has taken the lead with a 1.2 GHz on
order, while Riken in Japan already has the first single-story 1.0
GHz NMR installed.
NSF has also funded two 1.1 GHz NMRs, with a solid-state
research system recently installed at the University of
Wisconsin-Madison (www.wisc.edu), and a liquids research system on
order for the Complex Carbohydrate Research Center
(www.ccrc.uga.edu) at the University of Georgia. Together with the
1.1 GHz at St. Jude’s Children’s Research Hospital
(www.stjude.org), these ultra-high field instruments can enable
significant advancements in US scientific research.
Finally, with high interest recently also in compact,
single-story 4 Kelvin 1.0 GHz NMRs, there are now nine 1.0 GHz
systems installed at customer sites, with six in Europe, and one
1.0 GHz system each in Israel, Canada and Japan (including earlier
two-story 2 Kelvin magnets).
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high performance scientific instruments and high
value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular and cell biology research, in applied and pharma
applications, in microscopy and nanoanalysis, as well as in
industrial applications. Bruker offers differentiated, high-value
life science and diagnostics systems and solutions in preclinical
imaging, clinical phenomics research, proteomics and multiomics,
spatial and single-cell biology, functional structural and
condensate biology, as well as in clinical microbiology and
molecular diagnostics. For more information, please visit:
www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231219164773/en/
Investor: Justin Ward Sr. Director, Investor Relations
& Corporate Development Bruker Corporation T: +1 (978) 313-5800
E: Investor.Relations@bruker.com
Media: Markus Ziegler Sr. Director and Head of Group
Marketing Bruker BioSpin T: +49 172 3733531 E: pr@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
Von Mai 2023 bis Mai 2024